Pharming Group N.V. Files Form 6-K
Ticker: PHAR · Form: 6-K · Filed: Oct 6, 2025 · CIK: 1828316
| Field | Detail |
|---|---|
| Company | Pharming Group N.V. (PHAR) |
| Form Type | 6-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $10 million, $7 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, press-release, regulatory-filing
TL;DR
Pharming Group N.V. filed a 6-K on Oct 6, 2025, likely with a press release. Check it for updates.
AI Summary
Pharming Group N.V. filed a Form 6-K on October 6, 2025, to furnish a press release dated October 6, 2025. The filing does not contain specific financial figures or operational updates beyond the provision of this press release.
Why It Matters
This filing indicates Pharming Group N.V. is providing an update, likely through the attached press release, which could contain important business or financial information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (Form 6-K) to furnish a press release, not a report with significant new financial data or strategic changes.
Key Players & Entities
- Pharming Group N.V. (company) — Registrant
- October 6, 2025 (date) — Filing and Press Release Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to furnish a press release dated October 6, 2025, as required for foreign private issuers.
What is the filing date of this Form 6-K?
This Form 6-K was filed on October 6, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Pharming Group N.V.
What is the principal executive office address of Pharming Group N.V.?
The principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.
Which exhibit is furnished with this Form 6-K?
Exhibit 99.1, a press release of Pharming Group N.V., is furnished with this Form 6-K.
Filing Stats: 870 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-10-06 11:45:49
Key Financial Figures
- $10 million — to reduce total GA expenses by 15% or US$10 million annually and anticipate one-time restru
- $7 million — me restructuring costs of approximately $7 million to be recorded in the fourth quarter of
Filing Documents
- pharminggroupprovidesupdat.htm (6-K) — 25KB
- logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
- logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
- 0001828316-25-000045.txt ( ) — 193KB
Forward-looking Statements
Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred t